GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cryo-Cell International Inc (FRA:ZCY) » Definitions » EBITDA Margin %

Cryo-Cell International (FRA:ZCY) EBITDA Margin % : 15.44% (As of Feb. 2024)


View and export this data going back to 1990. Start your Free Trial

What is Cryo-Cell International EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cryo-Cell International's EBITDA for the three months ended in Feb. 2024 was €1.12 Mil. Cryo-Cell International's Revenue for the three months ended in Feb. 2024 was €7.28 Mil. Therefore, Cryo-Cell International's EBITDA margin for the quarter that ended in Feb. 2024 was 15.44%.


Cryo-Cell International EBITDA Margin % Historical Data

The historical data trend for Cryo-Cell International's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cryo-Cell International EBITDA Margin % Chart

Cryo-Cell International Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.27 23.18 18.41 21.92 -33.23

Cryo-Cell International Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.22 16.05 24.87 -199.99 15.44

Competitive Comparison of Cryo-Cell International's EBITDA Margin %

For the Medical Care Facilities subindustry, Cryo-Cell International's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cryo-Cell International's EBITDA Margin % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Cryo-Cell International's EBITDA Margin % falls into.



Cryo-Cell International EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Cryo-Cell International's EBITDA Margin % for the fiscal year that ended in Nov. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Nov. 2023 )/Revenue (A: Nov. 2023 )
=-9.625/28.962
=-33.23 %

Cryo-Cell International's EBITDA Margin % for the quarter that ended in Feb. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Feb. 2024 )/Revenue (Q: Feb. 2024 )
=1.124/7.279
=15.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cryo-Cell International  (FRA:ZCY) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Cryo-Cell International EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Cryo-Cell International's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cryo-Cell International (FRA:ZCY) Business Description

Traded in Other Exchanges
Address
700 Brooker Creek Boulevard, Suite 1800, Oldsmar, FL, USA, 34677
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of Prepacyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. All the business activity of the group functions through the United States and it derives revenue from processing and testing fees and storage fees charged each year for storage and through sales of the Prepacyte CB units.

Cryo-Cell International (FRA:ZCY) Headlines

No Headlines